Overview

Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to transforming the lives of patients with rare disorders through innovative gene therapies

Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders

We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy

Our mission is to be a leading global, fully integrated company delivering innovative gene therapies that transform the lives of patients with rare disorders

Management Team

Orchard's Leadership team brings more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for rare diseases

Mark Rothera
Mark Rothera
President & Chief Executive Officer
Stewart Craig
Stewart Craig
Chief Manufacturing Officer
Anne Dupraz-Poiseau
Anne Dupraz-Poiseau
Chief Regulatory Officer
Bobby Gaspar
Bobby Gaspar
Chief Scientific Officer
Nicolas Koebel
Nicolas Koebel
Chief of Staff & Head of Program Management
Adrien Lemoine
Adrien Lemoine
VP Business Development
Andrea Spezzi
Andrea Spezzi
Chief Medical Officer

Scientific Advisory Board

Orchard's Scientific Advisory Board brings together the world's leading scientists and clinicians in the field of gene therapy. Orchard is partnered with University College London, Great Ormond Street Hospital and University of Manchester in the United Kingdom, Genethon in France, as well as University of California Los Angeles and Boston Children's Hospital in the United States

Board of Directors

Benjamin Auspitz
Benjamin Auspitz
Bobby Gaspar
Bobby Gaspar
Alex Pasteur
Alexander Pasteur
Mark Rothera
Mark Rothera

Investors

F-Prime Capital
  • Leading international venture capital firm with focus on healthcare and life sciences
  • Over $1 billion under management in healthcare-dedicated venture funds
  • Backed by Fidelity Investments ($5 trillion in customer assets)
  • Global reach: 80 investments located in United States, Europe, Japan, China, India
Investment focus
  • Focus on bringing new products to market
  • F-Prime companies have delivered seven products to regulatory approval
  • Strong interest in rare disease, gene therapy, gene editing and cell therapy
“UCL
UCL Business PLC
  • UCL Business PLC is a leading technology transfer company
  • Commercializes innovations arising from University College London, one of the world's top research-led universities
  • Commercializes innovations arising from partner hospitals University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital
  • Invests in innovations through the UCL Technology Fund